Once-Weekly Insulin Icodec in Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Clinical Trials (ONWARDS Clinical Program).
Giuseppe LiscoAnna De TullioVincenzo De GeronimoVito Angelo GiagulliEdoardo GuastamacchiaGiuseppina PiazzollaOlga Eugenia DisoteoTriggiani VincenzoPublished in: Biomedicines (2024)
Insulin Icodec is substantially non-inferior to once-daily insulin analogs in T2D, either insulin-naïve or insulin-treated. However, Icodec works slightly better than competitors when used in a basal-only rather than basal-bolus regimen. Weight gain and hypoglycemic risk are substantially low but not negligible. Patients' education, adequate lifestyle and pharmacological interventions, and appropriate therapy adjustments are essential to minimize risks. This systematic review is registered as PROSPERO CRD42024568680.
Keyphrases
- type diabetes
- glycemic control
- systematic review
- weight gain
- end stage renal disease
- body mass index
- newly diagnosed
- weight loss
- quality improvement
- cardiovascular disease
- healthcare
- ejection fraction
- metabolic syndrome
- chronic kidney disease
- stem cells
- prognostic factors
- randomized controlled trial
- meta analyses
- climate change
- insulin resistance
- risk assessment
- mesenchymal stem cells
- human health
- preterm birth
- molecular dynamics simulations
- smoking cessation